GSK

EU agrees purchase deal for Sanofi/GSK COVID-19 vaccine

Credit: REUTERS/CHARLES PLATIAU

The European Union has agreed an advance purchase agreement with Sanofi and GlaxoSmithKline to buy the companies' potential COVID-19 vaccine, according to a tweet from European Health Commissioner Stella Kyriakides.

BRUSSELS, Sept 18 (Reuters) - The European Union has agreed an advance purchase agreement with Sanofi SASY.PA and GlaxoSmithKline SASY.PAGSK.L to buy the companies' potential COVID-19 vaccine, according to a tweet from European Health Commissioner Stella Kyriakides.

The agreement is the second such deal struck by the European Union. Kyriakides said she was hosting the signature of the contract.

The deal, for all 27 EU countries, covers the purchase of 300 million doses.

In return for the right to the doses, the European Commission will finance part of the upfront costs faced by vaccine producers. The vaccine doses themselves would be bought by EU countries.

(Reporting by Philip Blenkinsop and Jan Strupczewski, editing by Marine Strauss)

((philip.blenkinsop@thomsonreuters.com; +32 2 585 2869; Reuters Messaging: philip.blenkinsop.thomsonreuters.com@reuters.net))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

GSK

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More